July 05, 2017 Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration
June 27, 2017 Strongbridge Biopharma plc Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome
June 27, 2017 Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA
June 21, 2017 Final price in BONESUPPORT™’s initial public offering set at SEK 29 per share – trading on Nasdaq Stockholm commences today